Serguei V. S. Pakhomov, Jacob Solinsky, Martin Michalowski, Veronika Bachanova
{"title":"通过自动强化观察及早发现药物神经毒性效应的对话式代理。","authors":"Serguei V. S. Pakhomov, Jacob Solinsky, Martin Michalowski, Veronika Bachanova","doi":"10.1142/9789811286421_0003","DOIUrl":null,"url":null,"abstract":"We present a fully automated AI-based system for intensive monitoring of cognitive symptoms of neurotoxicity that frequently appear as a result of immunotherapy of hematologic malignancies. Early manifestations of these symptoms are evident in the patient's speech in the form of mild aphasia and confusion and can be detected and effectively treated prior to onset of more serious and potentially life-threatening impairment. We have developed the Automated Neural Nursing Assistant (ANNA) system designed to conduct a brief cognitive assessment several times per day over the telephone for 5-14 days following infusion of the immunotherapy medication. ANNA uses a conversational agent based on a large language model to elicit spontaneous speech in a semi-structured dialogue, followed by a series of brief language-based neurocognitive tests. In this paper we share ANNA's design and implementation, results of a pilot functional evaluation study, and discuss technical and logistic challenges facing the introduction of this type of technology in clinical practice. A large-scale clinical evaluation of ANNA will be conducted in an observational study of patients undergoing immunotherapy at the University of Minnesota Masonic Cancer Center starting in the Fall 2023.","PeriodicalId":34954,"journal":{"name":"Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing","volume":"31 4","pages":"24-38"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Conversational Agent for Early Detection of Neurotoxic Effects of Medications through Automated Intensive Observation.\",\"authors\":\"Serguei V. S. Pakhomov, Jacob Solinsky, Martin Michalowski, Veronika Bachanova\",\"doi\":\"10.1142/9789811286421_0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We present a fully automated AI-based system for intensive monitoring of cognitive symptoms of neurotoxicity that frequently appear as a result of immunotherapy of hematologic malignancies. Early manifestations of these symptoms are evident in the patient's speech in the form of mild aphasia and confusion and can be detected and effectively treated prior to onset of more serious and potentially life-threatening impairment. We have developed the Automated Neural Nursing Assistant (ANNA) system designed to conduct a brief cognitive assessment several times per day over the telephone for 5-14 days following infusion of the immunotherapy medication. ANNA uses a conversational agent based on a large language model to elicit spontaneous speech in a semi-structured dialogue, followed by a series of brief language-based neurocognitive tests. In this paper we share ANNA's design and implementation, results of a pilot functional evaluation study, and discuss technical and logistic challenges facing the introduction of this type of technology in clinical practice. A large-scale clinical evaluation of ANNA will be conducted in an observational study of patients undergoing immunotherapy at the University of Minnesota Masonic Cancer Center starting in the Fall 2023.\",\"PeriodicalId\":34954,\"journal\":{\"name\":\"Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing\",\"volume\":\"31 4\",\"pages\":\"24-38\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1142/9789811286421_0003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Computer Science\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1142/9789811286421_0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Computer Science","Score":null,"Total":0}
引用次数: 0
摘要
我们介绍了一种基于人工智能的全自动系统,用于密集监测血液恶性肿瘤免疫治疗过程中经常出现的神经毒性认知症状。这些症状的早期表现以轻微失语和意识模糊的形式在患者的言语中显现,可以在出现更严重和可能危及生命的损害之前检测出来并进行有效治疗。我们开发了自动神经护理助手(ANNA)系统,旨在通过电话在输注免疫疗法药物后的 5-14 天内每天多次进行简短的认知评估。ANNA 使用基于大型语言模型的对话代理,在半结构化对话中诱导自发言语,然后进行一系列基于语言的简短神经认知测试。在本文中,我们分享了 ANNA 的设计和实施、试点功能评估研究的结果,并讨论了在临床实践中引入此类技术所面临的技术和后勤挑战。从 2023 年秋季开始,明尼苏达大学松下癌症中心将对接受免疫疗法的患者进行观察研究,对 ANNA 进行大规模临床评估。
A Conversational Agent for Early Detection of Neurotoxic Effects of Medications through Automated Intensive Observation.
We present a fully automated AI-based system for intensive monitoring of cognitive symptoms of neurotoxicity that frequently appear as a result of immunotherapy of hematologic malignancies. Early manifestations of these symptoms are evident in the patient's speech in the form of mild aphasia and confusion and can be detected and effectively treated prior to onset of more serious and potentially life-threatening impairment. We have developed the Automated Neural Nursing Assistant (ANNA) system designed to conduct a brief cognitive assessment several times per day over the telephone for 5-14 days following infusion of the immunotherapy medication. ANNA uses a conversational agent based on a large language model to elicit spontaneous speech in a semi-structured dialogue, followed by a series of brief language-based neurocognitive tests. In this paper we share ANNA's design and implementation, results of a pilot functional evaluation study, and discuss technical and logistic challenges facing the introduction of this type of technology in clinical practice. A large-scale clinical evaluation of ANNA will be conducted in an observational study of patients undergoing immunotherapy at the University of Minnesota Masonic Cancer Center starting in the Fall 2023.